Riskpilot← Back to searchSign inGet full accessMYCOTECH PHARMA AS
ASActiveOrg 928974847Mustads Vei 1A, 0283 OsloRetail sale of other food · NACE 4727Est. 20225 employees
Revenue 2024
NOK 3,5M
+73% vs 2023
EBITDA margin
-655.9%
-27% vs 2023
Equity ratio
36.5%
Financial strength
Net profit 2024
NOK -24,8M
-32% vs 2023
| Revenue | NOK 3,5M | +73% |
| EBITDA | NOK -23,1M | -27% |
| Net profit | NOK -24,8M | -32% |
| Total assets | NOK 55,2M | -18% |
| Equity | NOK 20,2M | +34% |
| Employees | 5 | — |
Legal name
MYCOTECH PHARMA AS
Org number
928974847
Legal form
Aksjeselskap
NACE code
4727 · Retail sale of other food
Founded
23. mars 2022
Share capital
NOK 11 284 122
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Utvikle, distribuere og selge ernæringsprodukter og farmasøytiske produkter samt tilknyttede tjenester med mer, samt investering i annen virksomhet.
Address
Mustads Vei 1A, 0283 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 1 196 | 2 033 | 3 527 |
| Staff expenses | −284 | −6 378 | −13 785 |
| EBITDA | −6 358 | −18 161 | −23 132 |
| Depreciation & amort. | −4 341 | −6 310 | −6 435 |
| EBIT | −10 700 | −24 471 | −29 567 |
| Net financials | −698 | −1 444 | −901 |
| Profit before tax | −11 398 | −25 915 | −30 468 |
| Tax | −0 | −7 164 | −5 637 |
| Net profit | −11 398 | −18 751 | −24 832 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 41 954 | 67 273 | 55 199 |
| Equity | 8 420 | 15 069 | 20 157 |
| Long-term debt | 31 722 | 47 357 | 26 981 |
| Short-term debt | 1 812 | 4 846 | 8 060 |
| Total debt | 33 534 | 52 204 | 35 042 |
EBITDA margin
-655.9%
This company
15.8%
Market median
-4251% vs market
20222024
Equity ratio
36.5%
This company
38.2%
Market median
+4% vs market
20222024
Return on equity
-123.2%
This company
18.4%
Market median
-770% vs market
20222024
Net profit margin
-704.1%
This company
8.1%
Market median
-8793% vs market
20222024
Asset turnover
0.06×
This company
1.12×
Market median
-95% vs market
20222024
Debt / equity
1.74×
This company
0.62×
Market median
-181% vs market
20222024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RS Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KØ | Board of Directors | 2023 | — | — |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Immunopharma As | Company | 97.8% | 97.8% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Immunopharma As
MYCOTECH PHARMA AS Board members of MYCOTECH PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ralf Schmidt | Chief Executive Officer | 0 companies |
| Kim Øien | Board of Directors | 0 companies |
| Jörg Arndt Grünwald | Board of Directors | 0 companies |
| Frode Marc Bohan | Board of Directors | 0 companies |
| Knut Christian Espeseth | Chairman | 0 companies |
| Axel Henrik Johan Wollan | Board of Directors | 0 companies |
| Kjetil Ramsøy | Chairman | 0 companies |